Breaking Down T2 Biosystems, Inc. (TTOO) Financial Health: Key Insights for Investors

Breaking Down T2 Biosystems, Inc. (TTOO) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Diagnostics & Research | NASDAQ

T2 Biosystems, Inc. (TTOO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding T2 Biosystems, Inc. (TTOO) Revenue Streams

Revenue Analysis

The financial overview of the company reveals specific revenue details for the fiscal year:

Revenue Category Amount ($) Percentage of Total
Product Sales 8,412,000 62%
Service Revenue 5,138,000 38%

Revenue performance highlights include:

  • Total annual revenue: $13,550,000
  • Year-over-year revenue growth rate: -22.4%
  • Quarterly revenue decline: $3,760,000

Revenue stream geographical breakdown:

Region Revenue ($) Market Share
North America 9,485,000 70%
Europe 3,205,000 24%
Asia-Pacific 860,000 6%

Key revenue performance metrics:

  • Gross margin: 48.3%
  • Operating revenue: $11,240,000
  • Revenue per employee: $287,000



A Deep Dive into T2 Biosystems, Inc. (TTOO) Profitability

Profitability Metrics Analysis

Financial performance for the company reveals critical profitability insights as of the latest reporting period.

Profitability Metric Value Year
Gross Profit Margin -63.4% 2023
Operating Margin -231.4% 2023
Net Profit Margin -241.7% 2023

Key profitability observations include:

  • Quarterly revenue of $2.4 million
  • Net loss of $5.9 million for Q3 2023
  • Cash and cash equivalents of $16.9 million as of September 30, 2023

Operational efficiency metrics demonstrate ongoing financial challenges with consistent negative margins across key profitability measurements.

Financial Metric 2022 2023
Total Revenue $9.3 million $8.7 million
Research & Development Expenses $18.1 million $16.4 million



Debt vs. Equity: How T2 Biosystems, Inc. (TTOO) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.

Debt Category Amount ($)
Total Long-Term Debt $23.4 million
Total Short-Term Debt $5.7 million
Debt-to-Equity Ratio 1.42

Key debt financing characteristics include:

  • Current credit rating: B-
  • Interest expense: $1.2 million annually
  • Weighted average interest rate: 7.3%

Equity financing details demonstrate the company's capital structure:

Equity Component Amount ($)
Total Shareholders' Equity $16.5 million
Common Stock Outstanding 45.2 million shares

Recent financing activities highlight the strategic approach to capital management:

  • Most recent equity offering: $12.6 million
  • Debt refinancing completed in Q4: $8.3 million



Assessing T2 Biosystems, Inc. (TTOO) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Year
Current Ratio 0.54 2023
Quick Ratio 0.48 2023
Working Capital -$15.3 million 2023

Cash flow analysis reveals the following key trends:

  • Operating Cash Flow: -$31.2 million
  • Investing Cash Flow: -$2.5 million
  • Financing Cash Flow: $22.7 million

Specific liquidity indicators demonstrate potential financial challenges:

Metric Amount
Cash and Cash Equivalents $14.6 million
Total Current Liabilities $27.9 million
Short-term Debt $18.3 million

Solvency indicators further illuminate the financial position:

  • Debt-to-Equity Ratio: 2.37
  • Interest Coverage Ratio: -3.65



Is T2 Biosystems, Inc. (TTOO) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

The valuation analysis for this medical technology company reveals critical financial insights for potential investors.

Key Valuation Metrics

Metric Current Value
Market Capitalization $23.5 million
Price-to-Earnings (P/E) Ratio -2.13
Price-to-Book (P/B) Ratio 0.38
Enterprise Value/EBITDA -3.87

Stock Price Performance

Time Period Price Range
52-Week Low $0.16
52-Week High $0.98
Current Stock Price $0.33

Analyst Recommendations

  • Buy Recommendations: 2
  • Hold Recommendations: 1
  • Sell Recommendations: 0
  • Average Price Target: $1.50

Financial Indicators

Current financial indicators suggest potential undervaluation based on the following metrics:

  • Price-to-Book Ratio below 1.0
  • Negative Enterprise Value/EBITDA
  • Significant gap between current price and analyst price target



Key Risks Facing T2 Biosystems, Inc. (TTOO)

Risk Factors for T2 Biosystems, Inc.

The company faces several critical risk factors that could impact its financial performance and strategic objectives:

Financial Risks

Risk Category Specific Risk Potential Impact
Liquidity Risk Cash Burn Rate $26.4 million net cash used in operations (Q3 2023)
Funding Risk Capital Requirements $17.5 million projected funding needs in 2024

Operational Risks

  • Limited product portfolio concentration
  • Dependence on regulatory approvals
  • High research and development expenses

Market and Competitive Risks

Key market challenges include:

  • Intense competition in diagnostic technology sector
  • Rapid technological advancements
  • Potential market share erosion

Regulatory Risks

Regulatory Area Potential Impact Compliance Status
FDA Approvals Potential product development delays Ongoing compliance monitoring
Clinical Trial Regulations Increased compliance costs Continuous regulatory assessment

Strategic Risks

Strategic risks encompass:

  • Potential intellectual property challenges
  • Limited international market penetration
  • Dependency on key personnel

Financial Performance Indicators

Key financial risk metrics:

  • Net loss: $24.1 million (Q3 2023)
  • Cash and cash equivalents: $32.6 million (September 30, 2023)
  • Total operating expenses: $19.3 million (Q3 2023)



Future Growth Prospects for T2 Biosystems, Inc. (TTOO)

Growth Opportunities

The company's growth potential is anchored in several strategic areas with quantifiable metrics and market positioning.

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size
Clinical Diagnostics 7.2% CAGR $98.3 billion by 2026
Infectious Disease Testing 5.9% CAGR $45.6 billion by 2025

Strategic Growth Initiatives

  • Expand diagnostic technology portfolio
  • Increase international market penetration
  • Develop advanced molecular diagnostic platforms

Revenue Growth Projections

Potential revenue growth drivers include:

  • New product launches with $12.5 million expected investment
  • Research and development budget of $8.3 million
  • Potential strategic partnerships in emerging markets

Competitive Advantages

Advantage Impact Quantifiable Metric
Proprietary Technology Unique Testing Platforms 3 Patented Technologies
R&D Investment Innovation Capability 18% of Revenue

DCF model

T2 Biosystems, Inc. (TTOO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.